Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxidectin Dose Finding in Scabies
NCT03905265Phase 2Completed
- Sponsor
- Medicines Development for Global Health
- Start
- Jan 2020
- Primary completion
- Feb 2022
- Modality
- Allosteric Modulators
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of moxidectin in scabies (4 arms), sponsored by Medicines Development for Global Health. Primary endpoints: Mortality Rate for Adult Scabies Mites at 28 days and Summary of Participants With Most Commonly Occurring Adverse Events. Started Jan 2020; status: completed.
02
Drugs
moxidectin
03
Conditions
scabies
Beyond the preview
Go deeper on NCT03905265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905265.